

Supplement 2: Panelists Disclosure of Interests Forms

Pablo Alonso

Cihan Ay

Marc Carrier

Marcello DiNisio

Lisa Hicks

Alok Khorana

Andrew Leavitt

Agnes Lee

Gary Lyman

Fergus Macbeth

Rebecca Morgan

Simon Noble

Holger Schünemann

David Stenejhem

Elizabeth Sexton



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Boehringer Ingelheim	Investigator initiated Dabigatran trial in non-cardiac surgical patients with perioperative myocardial infarction.	Site principal investigator or	December 2017	4/20/2015: Dr. Alonso confirmed by email that funding goes to his institution and that he is the site PI (he reports to a PI located in Canada). By our guidelines, this interest is therefore not a COI.
Roche	I have coauthored an economic analysis about the use of self-monitoring of anticoagulation or dabigatran in patients with atrial fibrillation. Funding goes to my institution. Roche manufactures self-monitoring devices.	Co-investigator. The actual work was mostly done by two health economist		Not a COI because all funding went to his institution, he did not have a leadership role, and the subject of the analysis is not directly related to VTE in patients with cancer.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
	No idea what drugs Roche manufactures.			

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Prevention and Treatment of VTE in Patients with Cancer

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

- Don't know
- No
- Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Controversy is not a problem if the work is rigorous (which it will)

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Primary care

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Prevention and Treatment of VTE in Patients With Cancer
----------------------------	--

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Reviewer Name and Date</i>	<i>Notes</i>
Yes	Unconflicted majority	No	04/20/2015; 4/26/2015	
Yes	Unconflicted majority		6/12/2020 Alexander	On 6/12/2020, Dr. Alonso confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:

--



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Daiichi Sankyo	Service on an advisory board	February 2015	Ended before appointment
Bayer Austria	Speaker bureau involvement	current	COI: Bayer markets rivaroxaban
Pfizer and BMS	Speaker bureau involvement	current	COI: Pfizer and BMS market apixaban
Sanofi	Speaker bureau involvement	November 2013	Ended before appointment

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

- Column 1 Name the company funding or supporting the research.
- Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.
- Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.
- Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Prevention and Treatment of VTE in Patients with Cancer

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

I have (co)authored review articles related to the topic of these guidelines:

Ay C, Pabinger I. [VTE risk assessment in cancer. Who needs prophylaxis and who does not?](#) *Hamostaseologie*. 2015 Mar 5; 35(2).

Pabinger I, Ay C. [Risk of venous thromboembolism and primary prophylaxis in cancer. Should all patients receive thromboprophylaxis?](#) *Hamostaseologie*. 2012; 32(2):132-7. doi: 10.5482/ha-1173.

Ay C, Pabinger I. [Treatment and secondary prevention of venous thromboembolism in cancer patients. Current strategies and new therapeutic options.](#) *Hamostaseologie*. 2012;32(2):139-44. doi: 10.5482/ha-1168.

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I am a young early career academic researcher and would hope that my work on this panel would help me to further develop my career in academia (at my institution)

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Internal Medicine, Haematology

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

As a medical doctor, I am involved in the management of VTE in patients with cancer and prescribe treatments for cancer-associated VTE. I also recommend how to manage a suspected VTE in patients with cancer including diagnostic approaches.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Prevention and Treatment of VTE in Patients with Cancer
----------------------------	--

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Reviewer Name and Date</i>	<i>Notes</i>
Yes	Conflicted minority	Yes	04/20/2015; 5/5/2015	
Yes			6/1/2020 Alexander	On 5/28/2020, Dr. Ay confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
BMS	Personal income from participation on speakers bureau	04/14/2015	COI: Pfizer and BMS market apixaban.
Pfizer	Personal income from participation on speakers bureau	04/14/2015	COI: Pfizer and BMS market apixaban.
Bayer Austria	Personal income from participation on speakers bureau	04/14/2015	COI: Bayer markets rivaroxaban.

Notes:

--



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
LEO Pharma	Tinzaparin in patient undergoing colon surgery. In-kind support (tinzaparin provided). Funding goes to institution	PI	ongoing	COI even though funding goes to his institution, Leo is an affected company, (markets tinzaparin) + leadership role + Dr. Carrier’s research is VTE related
BMS	Apixaban in patients undergoing chemotherapy. In-kind support (apixaban provided). Funding goes to institution	PI	ongoing	COI, even though funding goes to his institution: affected company (BMS markets apixaban) + leadership role

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Prevention and Treatment of VTE in Patients with Cancer

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

International Society of Thrombosis and Haemostasis sub-committee Thrombosis & Malignancy
Guidance documents (challenges, upper extremity DVT and incidental DVT): J Thromb Haemost.
2014 May;12(5):796-800; J Thromb Haemost. 2013 Sep;11(9):1760-5.

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
Both projects under Part A Question 4 are funded by the Canadian Institute of Health Research	See description Part A Question 4	PI	ongoing

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Excellent support from the Ottawa Hospital Research Institute

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty? Hematology

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain: I am a Hematologist specializing in Thrombosis Medicine

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Prevention and Treatment of VTE in Patients with Cancer
----------------------------	--

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Reviewer Name and Date</i>	<i>Notes</i>
Yes	Conflicted minority	No	04/15/2015; 4/25/2015	
Yes	Conflicted minority		6/1/2020 Alexander	On 5/26/2020, Dr. Carrier confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Leo Pharma	Leadership role for a study of tinzaparin in patients undergoing colon surgery receiving in-kind support from Leo Pharma	04/12/2015	Leo markets tinzaparin.
BMS	Leadership role for a study of apixaban in patients undergoing chemotherapy receiving in-kind support from BMS	04/12/2015	BMS markets apixaban.
Pfizer	Leadership role for a study of dalteparin in obese patients with cancer-associated thrombosis receiving in-kind support from Pfizer	5/26/2020	Pfizer markets apixaban and dalteparin.

Notes:

--

Part D. New Declarations

The following interests were disclosed after appointment:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Bristol Myers Squibb	This activity ended in 2019.	5/26/2020	This is an update to Part A, Question 4.
Pfizer	Dalteparin in obese patients with cancer-associated thrombosis. In-kind support (dalteparin provided). Funding goes to institution. Dr. Carrier is the PI.	5/26/2020	COI. Pfizer markets apixaban, the subject of the research is related to the guideline topic, and Dr. Carrier has a leadership role. However, all funding goes to his institution.
N/A	<p>Kimpton M, Carrier M. What's new in the prevention and treatment of cancer-associated thrombosis? Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):158-166. Do</p> <p>Blood: Kraaijpoel N, Carrier M. How I treat Cancer-Associated Venous Thromboembolism. Blood. 2019 Jan 24;133(4):291-298</p> <p>ISTH: Wang TF, Zwicker JI, Ay C, Pabinger I, Falanga A, Antic D, Noble S, Khorana AA, Carrier M, Meyer G. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer</p>	5/26/2020	This is an update to Part B, Question 2.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	<p>patients: Guidance from the SSC of the ISTH.</p> <p>ISTH: Khorana AA, Noble S, Lee AYY, Soff G, Meyer G, O'Connell C, Carrier M. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018 Sep;16(9):1891-1894.</p>		



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Bayer Health Care	Consultancy	From 11-DEC-2014 to 11-DEC-2014	Ended before appointment
Grifols SPA	Service on an advisory board	From 10-NOV-2014 to 10-NOV-2014	Ended before appointment

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Thrombosis Research Institute, London. (Funding goes to institution)	Phase IV registry study to describe the acute and long term management, clinical and economic outcomes in patients with acute VTE	Local study coordinator	Ongoing	The Thrombosis Research Institute is a nonprofit organization.
Daiichi-Sankyo (Funding went to institution)	Phase IV registry study to describe the acute and long term management, clinical and economic outcomes in patients with acute VTE	Local sub-investigator	2014	Ended before appointment
Bayer Health Care (Funding goes to institution)	Phase III RCT on the long-term treatment of VTE with aspirin vs. rivaroxaban	Local sub-investigator	Ongoing	Bayer markets rivaroxaban. However, all funding for this trial goes to Dr. DiNisio’s institution, and he does not have a leadership role.
Daiichi-Sankyo (Funding goes to institution)	Phase III RCT on the treatment of VTE in cancer patients randomized to edoxaban or LMWH	Member of the Steering Committee (study has PI)	Ongoing	Daiichi-Sankyo markets edoxaban. However, all funding for this trial goes to Dr. DiNisio’s institution, and he does not have a leadership role (he is on the steering committee, but there is a PI).

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Prevention and Treatment of VTE in Patients with Cancer

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

I have authored and co-authored Cochrane reviews and other review articles on the topic of these guidelines. I also gave poster or meeting presentations.

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
University G. D'Annunzio (Study not funded)	Observational study registry on the treatment of incidental PE in cancer patients	Local study coordinator	Ongoing
University G. D'Annunzio (Study not funded)	Observational study on the role of D-dimer test and clinical decision rule in the diagnosis of DVT in cancer patients	Local study coordinator	Ongoing
University G. D'Annunzio (Study not funded)	Observational study about the use and outcomes of thromboprophylaxis for VTE in hospitalized cancer patients	Local study coordinator	Ongoing

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I believe I would not get any reaction. If any, I would get full support from my primary mentor and institution in these cases.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Internal Medicine and Vascular Medicine.

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

As part of my routine clinical practice in the outpatient service of Vascular Medicine I may have to advise VTE thromboprophylaxis or treatment in cancer patients as indicated.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Prevention and Treatment of VTE in Patients with Cancer
----------------------------	--

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Reviewer Name and Date</i>	<i>Notes</i>
Yes	Unconflicted majority	No	5/1/2015; 5/5/2015	
Yes	Conflicted minority	Yes	2/15/2017 Alexander; 2/21/2017 Kunkle	New interests disclosed. See Part D.
Yes	Conflicted minority	Yes	2/12/2018 Alexander	New interests disclosed. See Part D.
Yes	Conflicted minority	Yes	5/22/2020 Alexander	On 5/22/2020, Dr. Di Nisio confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Daiichi Sankyo	Direct payment for service on an advisory board (Feb 2016)	2/3/2017	Daiichi Sankyo markets edoxaban.
Daiichi Sankyo	Direct payment for consulting	2/3/2017	Daiichi Sankyo markets edoxaban.
Pfizer	Direct payment for service on an advisory board (November 2016)	2/3/2017	Pfizer markets apixaban.
Daiichi Sankyo	Direct payment for consulting	2/9/2018	COI. Daiichi Sankyo markets edoxaban.
Aspen	Direct payment for consulting	2/9/2018	COI. Aspen markets danaparoid and fondaparinux.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Pfizer	Direct payment for service on an advisory board	2/9/2018	COI. Pfizer markets apixaban.
Bayer Health Care	Direct payment for consulting	2/9/2018	COI. Bayer markets rivaroxaban.

Notes:

--

Part D. New Declarations

The following interests were disclosed after appointment:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Daiichi Sankyo	Direct payment for service on an advisory board (Feb 2016)	2/3/2017	COI. Daiichi Sankyo markets edoxaban.
Daiichi Sankyo	Direct payment for consulting	2/3/2017	COI. Daiichi Sankyo markets edoxaban.
Pfizer	Direct payment for service on an advisory board	2/3/2017	COI. Pfizer markets apixaban.
Daiichi Sankyo	Direct payment for consulting	2/9/2018	COI. Daiichi Sankyo markets edoxaban.
Aspen	Direct payment for consulting	2/9/2018	COI. Aspen markets danaparoid and fondaparinux.
Pfizer	Direct payment for service on an advisory board	2/9/2018	COI. Pfizer markets apixaban.
Bayer Health Care	Direct payment for consulting	2/9/2018	COI. Bayer markets rivaroxaban.
Daiichi Sankyo	Direct payment for speaking and consulting.	5/22/2020	COI. Daiichi Sankyo markets edoxaban.
Aspen	Direct payment for consulting	5/22/2020	COI. Aspen markets fondaparinux and danaparoid.
Pfizer	Direct payment for service on an advisory board and consulting.	5/22/2020	COI. Pfizer markets apixaban.
Daiichi Sankyo	Direct payment for consulting, speaking and service on an advisory board	5/22/2020	COI. Daiichi Sankyo markets edoxaban.
Bayer	Direct payment for service on an advisory board	5/22/2020	COI. Bayer markets rivaroxaban.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Werfen	Direct payment for consulting	5/22/2020	Not a COI. Werfen markets D-dimer assays, however Werfen does not market any products used in the treatment of VTE.
Bristol Myers Squibb	Direct payment for service on advisory board	5/22/2020	COI. BMS markets apixaban.
Sanofi-Aventis	Direct payment for consulting	5/22/2020	COI. Sanofi markets enoxaparin.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Thrombosis Research Institute, London.	<p>Phase IV registry study to describe the acute and long term management, clinical and economic outcomes in patients with acute VTE. This study was published in 2019.</p> <p>Observational study registry on the treatment of incidental PE in cancer patients was published in JCO 2019 (Kraaijpoel N et al, JCO 2019)</p>	5/22/2020	This is an update to Part A, Question 4.
Bayer Health Care	<p>Phase III RCT on the long-term treatment of VTE with aspirin vs. rivaroxaban. This study was published in 2018.</p> <p>Observational study about the use and outcomes of thromboprophylaxis for VTE in hospitalized cancer patients was published in Th Res 2018 (Di Nisio M et al, Th Res 2018)</p>	5/22/2020	This is an update to Part A, Question 4.



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Gilead (CIHR-industry grant)	RCT of tenofovir for patients with occult hepatitis B infection who are receiving rituximab for lymphoma	Co-PI	2016	NO COI: Gilead has no products that could be affected by guidelines on VTE in patients with cancer.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Prevention and Treatment of VTE in Patients with Cancer

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

My mentors and institution are supportive of my academic work including participation in guideline development. I anticipate strong support.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Hematology (I practice predominantly malignant hematology with a small amount of general, in-pt hematology as well).

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

I occasionally manage patients in my own practice with cancer associated VTE. As a member of an in-patient general hematology consult service I also occasionally provide advice to colleagues regarding the management of cancer associated VTEs.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Prevention and Treatment of VTE in Patients with Cancer
----------------------------	--

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Reviewer Name and Date</i>	<i>Notes</i>
Yes	Unconflicted majority	No	4/20/2015; 5/5/2015	
Yes			6/8/2020 Alexander	On 6/1/2020, Dr. Hicks confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:

Part D. New Declarations

The following interests were disclosed after appointment:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Blueprint Medicines	Study of avapritinib for systemic mastocytosis. Dr. Hicks is the local site PI.	6/1/2020	Not a COI. Blueprint Medicines does not market any products used in the treatment of VTE.



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Janssen	Consulting, will co-chair steering committee of upcoming study	current	COI: Janssen markets rivaroxaban.
Leo Pharma	Consulting, member of steering committee of CATCH trial	current	COI: Leo markets tinzaparin, a LMWH.
Pfizer	Consulting	2014	Ended before appointment
Boehringer Ingelheim	Consulting	2014	Ended before appointment
Genentech	Consulting	2014	Ended before appointment
Daiichi Sankyo	Consulting	2014	Ended before appointment
Halozyme	Consulting	2014	Ended before appointment
Angiodynamics	Consulting	2015	Angiodynamics markets technologies for venous disease and vascular access. However, these products are unlikely to be affected by guidelines on prevention or treatment of VTE.

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Prevention and Treatment of VTE in Patients with Cancer

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

I am replying no based on the framing of the question as ‘beliefs’ which would imply an opinion not grounded in fact. I do of course have a scientific viewpoint based on published evidence.

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

I co-chair ISTH clinical guidance statements on related topics and AMA member of ASCO guidelines panel on same topic

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
Scott Hamilton CARES Initiative	Pilot study of prophylaxis with aspirin and/or statin	PI	2016

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

Speak widely at conferences and grand rounds on this subject given my expertise in the area.

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

- Don't know
- No
- Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Institution would remain supportive

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Oncology

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

I take care of patients with this illness and of course I will diagnose/treat them appropriately

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Not sure, but would assume that I will continue to work in this field and that new opportunities will emerge

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Prevention and Treatment of VTE in Patients with Cancer
----------------------------	--

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Reviewer Name and Date</i>	<i>Notes</i>
Yes	Conflicted minority	Yes	5/1/2015; 5/5/2015	Dr. Khorana expects new interests that may be conflicting (see his response to Part B, question 10).
Yes	Conflicted minority	Yes	2/16/2017 Alexander; 2/21/2017 Kunkle	New disclosures. See Part D.
Yes	Conflicted minority	Yes	2/12/2018 Alexander	New disclosures. See Part D.
Yes	Conflicted minority		7/7/2020 Alexander	New disclosures. See Part D. On 7/1/2020, Dr. Khorana confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Janssen	Personal income from consulting. Will co-chair steering committee of upcoming study	04/16/2015	Janssen markets rivaroxaban.
Leo Pharma	Personal income from consulting. Member of steering committee of CATCH trial	04/16/2015	Leo markets tinzaparin, a LMWH.
Bayer	Personal income from consulting	02/16/2017	Bayer markets rivaroxaban.
Pfizer	Direct payment for consulting.	02/12/2018	COI. Pfizer markets apixaban.
Janssen	Direct payment for consulting.	02/12/2018	COI. Janssen markets rivaroxaban.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Bayer	Direct payment for consulting	02/12/2018	COI. Bayer markets rivaroxaban.

Notes:

--

Part D. New Declarations

The following interests were disclosed after appointment:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Bayer	Direct payment for consulting	02/16/2017	COI. Bayer markets rivaroxaban.
Halozyme	Direct payment for consulting	02/16/2017	Not an affected company. Halozyme does not market any devices or drugs used in the diagnosis or treatment of VTE.
Angiodynamics	Dr. Khorana anticipates consulting with Angiodynamics later this year.	02/16/2017	Angiodynamics markets technologies for venous disease and vascular access. However, these products are not expected to be addressed by guidelines on prevention or treatment of VTE.
Pfizer	Direct payment for consulting. This paid activity ended in December 2017.	02/12/2018	COI. Pfizer markets apixaban.
Janssen	Direct payment for consulting.	02/12/2018	COI. Janssen markets rivaroxaban.
Bayer	Direct payment for consulting	02/12/2018	COI. Bayer markets rivaroxaban.
PharmaCyte	Direct payment for consulting	02/12/2018	Not an affected company. Pharmacyte does not market any devices or drugs used in the diagnosis or treatment of VTE.
Pharmacyclics	Direct payments for consulting		Not an affected company. Pharmacyclics does not market any devices or drugs used in the

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
			diagnosis or treatment of VTE.
Bristol Myers Squibb	Direct payment for consulting	7/1/2020	COI. BMS markets apixaban.
Seattle Genetics (2018-2019)	Direct payment for consulting.	7/1/2020	Not a COI. Seattle Genetics does not market any drugs or devices used in the diagnosis or treatment of VTE.
Pfizer	Direct payment for consulting	7/1/2020	COI. Pfizer markets apixaban
Pharmacyclics	Direct payment for consulting	7/1/2020	Not a COI. Pharmacyclics does not market any drugs or devices used in the diagnosis or treatment of VTE.
Angiodymanics	Direct payment for consulting. This activity ended in 2018.	7/1/2020	This is an update to a previous disclosure.
Leo Pharma	Direct payment for consulting. This activity ended in 2018.	7/1/2020	This is an update to a previous disclosure.
Medscape	Direct payment for consulting.	7/1/2020	Not a COI. Medscape does not market any drugs or devices used in the treatment or diagnosis of VTE.
Merck	Research funding. Study of anti-cancer treatments. Site PI.	7/1/2020	Not a COI. Merck does not market any drugs or devices used in the treatment or diagnosis of VTE.
Array	Research funding. Study of anti-cancer treatments. Site PI.	7/1/2020	Not a COI. Array Biopharma does not market any drugs or devices used in the treatment or diagnosis of VTE.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Bristol Myers Squibb	Research funding. Study of anti-cancer treatments. Site PI.	7/1/2020	COI. BMS markets apixaban. However, Dr. Khorana does not have a leadership role, the subject of the research is unrelated to the guideline topic and all funding goes to Dr. Khorana's institution.
Leap	Research funding. Study of anti-cancer treatments. Site PI.	7/1/2020	Not a COI. Leap Pharmaceuticals does not market any drugs or devices used in the diagnosis or treatment of VTE.



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Pfizer	Advisory Board Mtg	Oct 24, 2014 (1 day mtg)	Ended before appointment

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
GE Healthcare	Hematopoietic stem cell expansion. Money goes to institution and used by me as a grant.	PI of an investigator initiated study. GE provided some of the funding. Univ. of Calif. provided the remainder. It is a grant offered through the Univ. of California Office of the President, call a UC Discovery Grant	2014	Not a COI: Funding ended before appointment

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Prevention and Treatment of VTE in Patients with Cancer

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain: I strongly believe that an excellent set of guidelines, derived from the current cumulative evidence in the literature, will be a very useful publication for clinicians and for patients.

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

UCSF is firmly dedicated to academic pursuits and the development of educational materials regardless of popular response. The institution does not shy away from controversy, nor does it seek controversy.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Internal Medicine & Hematology

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain: I take care of patients with venous thromboembolism, and some of them have cancer. Some of those patients I send for imaging to make the diagnosis, and for some/all I order lab tests that help in diagnosis/management.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Prevention and Treatment of VTE in Patients with Cancer
----------------------------	--

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Reviewer Name and Date</i>	<i>Notes</i>
Yes	Unconflicted majority	No	5/1/2015; 5/9/15	
Yes	Unconflicted majority	No	8/13/2015; 8/16/15	Disclosed new research funding from OPKO Health. See Part D.
Yes			7/15/2020 Alexander	On 7/7/2020, Dr. Leavitt confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Johnson and Johnson	Stock ownership.	7/7/2020	COI. Johnson and Johnson markets rivaroxaban.

Notes:

--

Part D. New Interests

The following interests were disclosed after appointment:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
OPKO Health Inc.	Site PI for phase I study for a long-acting Factor 7 product. Study will look at toxicity, with patients receiving a single injection (dose escalation) and safety and pharmacology data collected.	7/28/2015	Not a COI: Dr. Leavitt does not have a leadership role (site PI), and all payments will go directly to his institution.
Johnson and Johnson	Stock ownership.	7/7/2020	COI. Johnson and Johnson markets rivaroxaban. This disclosure was made after the recommendations were formed.
BioMarin	Direct payment for participation on an advisory board regarding hemophilia A gene therapy. Sep & Oct 2019	7/7/2020	Not a COI. BioMarin does not market any drugs used in the treatment of VTE.
Dova Pharmaceuticals	Direct payment for participation on an advisory board regarding ITP. Feb 2020.	7/7/2020	Not a COI. Dova Pharmaceuticals does not market any drugs used in the treatment of VTE.
Bio Products Laboratory	Direct payment for participation on an advisory board regarding Factor XI deficiency	7/7/2020	Not a COI. BPL does not market any drugs use in the treatment of VTE.
BioMarin	Research funding for clinical trial on hemophilia A gene therapy. Dr. Leavitt is the PI.	7/7/2020	Not a COI. BioMarin does not market any drugs used in the treatment of VTE.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Sangamo Therapeutics	Research funding for clinical trial on hemophilia A gene therapy. Dr. Leavitt is the PI.	7/7/2020	Not a COI. Sangamo Therapeutics does not market any drugs used in the treatment of VTE.
Pfizer	Research funding for clinical trial on hemophilia A and hemophilia B gene therapy. Dr. Leavitt is the PI.	7/7/2020	Not a COI. Pfizer markets apixaban and Dr. Leavitt has a leadership role. However, the subject of the research is unrelated to the guideline topic and all funding goes to his institution.
Kezar Life Sciences	Research funding for a study on ITP and AIHA. Dr. Leavitt is the PI.	7/7/2020	Not a COI. Kezar Life Sciences does not market any drugs used in the treatment of VTE.



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Avivia	Lecture to HCP on topic	May 2014	Ended before appointment
Bayer	Advisory board meeting	April 2015	Ended before appointment
Bristol-Myers Squibb	Advisory board meeting	October 2014	Ended before appointment
Boehringer Ingelheim	Lecture to HCP on Topic	May 2013	Ended before appointment
Daiichi Sankyo	Advisory Board	March 2014	Ended before appointment
Leo Pharma	Advisory board meeting and Principal investigator of a trial (now complete)	June 2015	COI: Leo markets tinzaparin, a LMWH.
Pfizer	Consultancy Advisory Board Member	May 2015	COI: Pfizer markets apixaban and dalteparin.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Sanofi Aventis	Lecture to HCP on topic	February 2014	Ended before appointment

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Bristol-Myer Squibb	Peer-reviewed (CIHR) funded RCT with study drug provided by BMS (apixaban and placebo)	Co-applicant in grant, site investigator	2017	BMS (with Pfizer) markets apixaban. However, funding is provided by CIHR, and Dr. Lee does not have a leadership role in this study.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Prevention and Treatment of VTE in Patients with Cancer

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

It is an important and common clinical topic for general hematologists and other physicians providing care to patients with cancer-associated thrombosis. More research in this population is needed.

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

I am a co-author of the ASCO guidelines and ISTH subcommittee guidance documents on the topic. I have written many review articles, including chapters for Hematology (ASH), book chapters and original articles on the topic. I have made many presentations on the topic at educational rounds,

local meetings, national and international conferences. Cancer-associated thrombosis is my area of research interest and expertise.

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I do not anticipate any change in support from my institution, mentor or other entities from working on this panel or authorship of these guidelines.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Hematology, specializing in thrombosis

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

I see patients with cancer-associated thrombosis on a regular basis in my clinical practice.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Prevention and Treatment of VTE in Patients with Cancer
----------------------------	--

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Reviewer Name and Date</i>	<i>Notes</i>
Yes	Conflicted minority	Yes	5/1/2015; 5/5/2015	
Yes	Conflicted minority	Yes	6/23/15	New potential COI added (BMS/Pfizer).
Yes	Conflicted minority	Yes	10/8/15; 10/15/15	New disclosures added to Part D: BMS research (previously described as a potential COI) and Bayer steering committee. The BMS research is a conflict.
Yes	Conflicted minority		5/28/2020 Alexander	On 5/26/2020, Dr. Lee confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Leo Pharma	Personal income from advisory board meeting and principal investigator of a trial (now complete)	4/27/15	Leo markets tinzaparin, a LMWH.
Pfizer	Personal income from consulting and service on an advisory board	4/27/15	Pfizer markets apixaban and dalteparin.
BMS	Leadership role for a study of apixaban supported by BMS	9/17/15	BMS markets apixaban.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:

--

Part D. New Interests

The following interests were disclosed after appointment:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Daiichi Sankyo	My centre will be participating in an international, investigator-initiated clinical trial using the study drug (edoxaban) supplied by Daiichi Sankyo later this year. I am the site PI and the study is expected to run for 2 years. I will not be receiving any funds personally. All funds will be directed to our hospitals' research institute to cover overhead and operational costs.	6/18/2015	Not a COI: Although Daiichi Sankyo is an affected company, markets edoxaban, Dr. Lee does not have a leadership role, she is Site PI. Also, all funds go to her institution.
BMS-Pfizer	I have applied to BMS-Pfizer to provide study drug apixaban and perform drug levels for a study that I designed. It is a single centre study with 24 patients. I have not received confirmation from BMS-Pfizer that it will support the study.	6/18/2015	Potential COI: BMS-Pfizer markets apixaban. Dr. Lee would have a leadership role if funding is approved. *See update below*
BMS	Investigator-initiated study will be supported by BMS, which will provide study drug and a grant of ~\$24,000 CDN to perform assays. The study is also supported by a peer-reviewed grant	9/17/15	COI: Although funding for this research goes to Dr. Lee's institution, BMS is an affected company (markets apixaban), and Dr. Lee has a leadership role.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
	<p>from the Canadian Hematology Society. I will not personally receive any funding for the study. In fact, I will be subsidizing the cost of the study with my own internal funds to pay for personnel and infrastructure.</p>		
<p>Bayer</p>	<p>Steering Committee of an industry-funded international registry looking at the use of anticoagulation in cancer patients. The work will be mainly done through teleconferencing so I will not be receiving an honorarium or need expenses reimbursed.</p>	<p>9/17/15</p>	<p>Not a COI: Dr. Lee will not receive any remuneration for her participation.</p>



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Amgen	PI on research grant to Fred Hutch	PI	12/31/2016	Not a COI: Amgen markets drugs for cancer but not for VTE. These guidelines are not expected to make recommendations about choice of cancer treatments.

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Prevention and Treatment of VTE in Patients with Cancer

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Guidelines from the American Society of Clinical Oncology

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

None

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Hematology and Oncology

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain: I will prescribe anticoagulation to patients with VTE

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publicly available.

Name of guideline panel(s)	Guideline Panel on Prevention and Treatment of VTE in Patients with Cancer
----------------------------	--

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Reviewer name and date</i>	<i>Notes</i>
Yes	Unconflicted majority	No	5/1/2015; 5/9/2015	
Yes	Unconflicted majority	No	2/16/2017 Alexander; 2/21/2017 Kunkle	New interests disclosed. See Part D.
Yes	Has some conflicts	N/A	8/28/2019 Alexander; 9/11/2019 Cuker, Kunkle, Pai, Panepinto, Rajasekhar	<p>In March 2017, Dr. Lyman reported new direct payments and research funding from companies that are not affected by the guidelines. See Part D.</p> <p>In August 2019, Dr. Lyman reported other activities, including by his spouse. Some of these activities are considered direct financial conflicts. See below and Part D.</p> <p>The guideline panel has already agreed on recommendations, and a manuscript report of the guidelines is drafted. The direct financial conflicts summarized below will be managed through disclosure in the published guidelines.</p>

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>
Pfizer	Travel reimbursement for consulting. Jan 2018.	8/25/2019	COI. Pfizer markets LMWH and apixaban.
Pfizer	Direct payment to spouse for consulting in December 2017	8/28/2019	COI. Pfizer markets LMWH and apixaban.
Bayer AG	Direct transfer of value (travel reimbursement) to spouse in October 2018	8/28/2019	COI. Bayer markets rivaroxaban.

Notes:

Part D. New Declarations

The following interests were disclosed after appointment:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
G1 Therapeutics	Direct payments for consulting around a new myeloid growth factor for neutropenia	2/13/17	Not an affected company.
Halozyme	Direct payments for consulting around the treatment of pancreatic cancer	2/13/17	Not an affected company.
Agendia	Research funding	3/15/2017	Not an affected company.
Amgen	Research funding – PI on research grant to Duke University	3/15/2017	Not an affected company.
Amgen	Research funding – PI on research grant to Fred Hutchinson Cancer Research Center	3/15/2017	Not an affected company.
Amgen	Research funding	3/15/2017	Not an affected company.
Celldex	Direct payment to spouse for consulting in June 2018.	3/15/2017	Not an affected company.
Genomic Health	Direct payment for consulting	3/15/2017	Not an affected company.
Helsinn	Direct payment for consulting	3/15/2017	Not an affected company.
Invitae	Direct payment for consulting	3/15/2017	Not an affected company.
Mylan	Direct payment for consulting	3/15/2017	Not an affected company.
Partners Healthcare	Direct payment for consulting	3/15/2017	Not an affected company.
Spectrum	Direct payment for consulting	3/15/2017	Not an affected company.

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Pfizer	Travel reimbursement for consulting. Jan 2018.	8/25/2019	COI. Pfizer markets LMWH and apixaban.
Pfizer	Direct payment to spouse for consulting in December 2017	8/28/2019	COI. Pfizer markets LMWH and apixaban.
Bayer AG	Direct transfer of value (travel reimbursement) to spouse in October 2018	8/28/2019	COI. Bayer markets rivaroxaban.
Agendia	Direct payment to spouse for consulting in December 2018	8/28/2019	Not an affected company
Mylan	Direct payment to spouse for consulting in February 2018	8/28/2019	Not an affected company.
Beyond Springs	Participation by spouse in consulting. No payment received.	8/28/2019	Not an affected company.
Spectrum Pharmaceuticals	Direct payment to spouse for consulting in February 2019	8/28/2019	Not an affected company.
Amgen	Participation by spouse in consulting. No payment received.	8/28/2019	Not an affected company.



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Pfizer	Randomised trial of dalteparin in patients with lung cancer (Fragmatic Trial). Pfizer provided in-kind support (dalteparin).	Chief Investigator	March 2015	Ended before appointment.

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Prevention and Treatment of VTE in Patients with Cancer

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Antithrombotic therapy and survival in patients with malignant disease. Kakkar AK, Macbeth F. Br J Cancer. 2010 Apr 13; 102 Suppl 1:S24-9.

I presented the interim results of the Fragmatic trial at the World Lung Cancer Conference in Sydney in 2013 and at the British Thoracic Oncology Group Meeting in Dublin in January 2014

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I would hope that they would respect my independent opinion and the robustness of the guideline process and support me.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

I worked as a clinical oncologist for many years but am now retired from active clinical practice. I have also worked for over 20 years in various roles on clinical guideline development, with 3 years until 2012 as Director of the Clinical Guidelines program at the National Institute for Health and Care Excellence (NICE).

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Prevention and Treatment of VTE in Patients with Cancer
----------------------------	--

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Date reviewed by ASH staff</i>	<i>Notes</i>
Yes	Unconflicted majority	No	5/1/2015; 5/5/2015	
Yes	Unconflicted majority	No	2/16/2015 Alexander; 2/21/2017 Kunkle	See Part D.
Yes			6/8/2020 Alexander	On 5/22/2020, Dr. Macbeth confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:

--

Part D. New Declarations

The following interests were disclosed after appointment:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
N/A	New publication: FRAGMATIC trial. Macbeth F, Noble S, Evans J, et al. J DOI: 10.1200/JCO.2015.64.0 268 <i>Journal of Clinical Oncology</i> 34, no. 5 (February 2016) 488- 494.	2/2/2017	Dr. Macbeth's role in this trial that was supported by Pfizer was previously disclosed: See Part A, Question 4. The trial and its funding ended in 2015, before Dr. Macbeth's appointment to this guideline panel.



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Prevention and Treatment of VTE in Patients with Cancer

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

None

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

None

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Prevention and Treatment of VTE in Patients with Cancer Heparin Induced Thrombocytopenia (systematic review) Thrombophilia (systematic review)
----------------------------	---

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Reviewer name and date</i>	<i>Notes</i>
Yes	Unconflicted majority	No	8/13/15; 8/16/15	
Yes	Unconflicted majority	No	7/8/2018 Alexander	On 7/8/2018, Ms. Morgan confirmed all information in this form.
Yes			6/8/2020 Alexander	On 6/8/2020, Ms. Morgan confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Pfizer	Speakers bureau	30/01/2015	Ended before appointment
Leo Pharma	Speakers Bureau	22/4/2015	Ended before appointment
BMS	Advisory Board	18/11/2014	Ended before appointment
Astra Zenaca	Advisory Board	14/10/2014	Ended before appointment

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Leo Pharma	Quality of life study: funding goes to institution. Monies to pay for transcription services of qualitative interviews. Investigator initiated research project.	CI	First part of study completed and published. Data analysis of sub studies ongoing	Leo markets tinzaparin, a LMWH. However, the study is mainly completed. Furthermore, Dr. Noble received no direct funding from Leo, and he did not have a leadership role.
Pfizer	FRAGMATIC: RCT of lung cancer patients receiving dalteparin	Co-Investigator	Completed. Paper submitted	Ended before appointment
Leo Pharma	Patient preference study I served on steering committee I took no fee I am lead author on manuscript	Co-Investigator	Completed	Ended before appointment

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Prevention and Treatment of VTE in Patients with Cancer

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

1. Noble S. Heparin and survival in cancer: where do we stand? *Thrombosis Research*. 2014 May; 133 Suppl 2:S133-8.
2. Debourdeau P, Farge-Bancel D, Beckers M, Baglin C, Bauersachs R, Brenner B, Brillhante D, Falanga A, Gerotziafas G, Haim N, Kakkar AK, Khorana A, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa S, Noble S, Pabinger I, Prins M, Qari M, Streiff M, Zervas K, Buller H, Bounameaux H. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. *Journal Thrombosis and Haemostasis* 2013 Jan; 11(1):71-80.
3. Farge-Bancel D, Debourdeau P, Beckers M, Baglin C, Bauersachs R, Brenner B, Brillhante D, Falanga A, Gerotziafas G, Haim N, Kakkar AK, Khorana A, Lecumberri R, Mandala M, Marty M,

- Monreal M, Mousa S, Noble S, Pabinger I, Prins M, Qari M, Streiff M, Zervas K, Bounameaux H, Buller H. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated in patients with cancer. *Journal Thrombosis and Haemostasis* 2013 Jan;11(1):56-70
4. Carrier M, Khorana AA, Zwicker JI, Noble S, Lee AYY Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. *Journal Thrombosis and Haemostasis* 2013 September; 11(9) 1760-65
 5. Treasure T, Akunne A, Balachander N, Browne J, Carter K, Carter S, Chong LY, Fiddian N, Frostick S, Gautam N, Gregg P, Head K, Hingorani A, Homer K, Hughes R, Hunt B, Langford N, Lewin H, Mainwaring P, McBride D, McPherson G, Noble S, Sharpin C, Sloan N, Stansby G, Walton P, Warwick D, Welch N, Wonderling D, Young A, Young C. Reducing the risk of venous thromboembolism in patients admitted to hospital: summary of NICE guidance. *BMJ*. 2010 Jan 27; 340:c95.
 6. Noble SI, Shelley M, Coles B, Williams S, Wilcock A, Johnson M. The management of venous thromboembolism in advanced cancer: a systematic review and meta-analysis by the thrombosis task group, on behalf of the Association for Palliative Medicine Science Committee. *Lancet Oncology* 2008, 9(6):577-84

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

Having previously served on the NICE guidelines (CG93) I know that my organization would be supportive should guidelines generate a strong reaction.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Clinical Reader in Palliative Medicine Cardiff University

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

I am involved in the management of cancer associated thrombosis and currently prescribe according to current ACCP Guidelines

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

I have already made a declaration that I shall take on no further advisory boards or take on research activities funded or supported by industry.

Furthermore, if ever involved in any speaking engagements, I shall take no financial or other sort of remunerations.

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Prevention and Treatment of VTE in Patients with Cancer
----------------------------	---

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Reviewer Name and Date</i>	<i>Notes</i>
Yes	Unconflicted majority	No	5/1/2015; 5/5/2015	Dr. Noble agrees to remain unconflicted during guideline development.
Yes	Unconflicted majority	No	2/14/2017 Alexander; 2/21/2017 Kunkle	New disclosure. See Part D.
Yes			6/8/2020 Alexander	On 5/26/2020, Dr. Noble confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:

--

Part D. New Declarations

The following interests were disclosed after appointment:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
N/A	Dr. Noble is now a Clinical Professor in Palliative Care at Cardiff School of Medicine.	02/02/2017	This is an update to Dr. Noble's previously disclosed professional specialty. See Part B, Question 8.



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Topic	Guideline Panel
Venous thromboembolism (VTE)	VTE Guideline Coordination Panel
Prevention of VTE in medical hospitalized patients	Guideline Panel on Prevention of VTE in Medical Hospitalized Patients
Prevention and treatment of VTE in patients with cancer	Guideline Panel on Prevention and Treatment of VTE in Patients with Cancer
Diagnosis of VTE	Guideline Panel on Diagnosis of VTE

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

- ACCP AT Guidelines
- CHEST since edition 6 to 9
- Cochrane reviews on antithrombotic use in patients with cancer
- NEJM editorial on update of a systematic review on antithrombotics with cancer

- JAMA Clinical Synopsis – heparin in cancer patients undergoing surgery

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

- No
- Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>
CIHR	Individual patient data meta-analysis antithrombotics in cancer	PI	Mach 2016

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

- Don't know
- No
- Yes

If yes, please explain:

Contract for systematic reviews for these guidelines being negotiated with ASH

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

N/A

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Internal Medicine, Public Health, preventive medicine

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Diagnosis and treatment of DVT

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	VTE Guideline Coordination Panel Guideline Panel on Diagnosis of VTE Guideline Panel on Prevention of VTE in Medical Hospitalized Patients Guideline Panel on Prevention and Treatment of VTE in Patients with Cancer
----------------------------	--

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Date reviewed by ASH staff</i>	<i>Notes</i>
Yes	Unconflicted majority	No	5/1/2015; 5/5/2015	
Yes	Unconflicted majority	No	4/26/2018 Alexander	On 4/26/2018, Dr. Schunemann confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

--	--	--	--

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.") Add rows as needed for each research project.

Company	Description of Research	My Role	End Date	For ASH Internal Use
CPP (Cancer Prevention Pharmaceuticals)	Oral interventional drug in the treatment of FAP (familial adenomatous polyposis) patients	Administrator Not funded on the project	08/14/2015	Not a COI: Research is not VTE related +she does not hold a leadership role.

My Partner's or Spouse's Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

VTE in Patients with Cancer

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain: It is integral to identify preventative opportunities to improve the standard of care of cancer patients so as not to add to their burden.

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.") Add rows as needed for each research project.

Funder	Description of Research	My Role	End Date
NIH	Colorectal cancer	Department Administrator/directed personnel and resources	08/14/2015
NIH	Breast cancer	Department Administrator/directed personnel and resources	08/14/2015
NIH	Melanoma	Department Administrator/directed personnel and resources	08/14/2015

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I will continue to be seen as a member of the community and would not unduly influence the institution I presently or formerly worked for.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Certified Rehabilitation Counselor. I only volunteer these services now and I work in an administrative role.

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Prevention and Treatment of VTE in Patients With Cancer
----------------------------	--

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Reviewer Name and Date</i>	<i>Notes</i>
Yes	Unconflicted majority	No	8/11/15; 8/16/15	
Yes	Unconflicted majority	No	6/10/2020 Alexander	On 6/10/2020, Ms. Sexton confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:

--



ASH Guideline Panel Declarations of Interest Form

Part A. Material Interests in Companies

Equity

1. Do you currently or in the past 24 months have you had equity in any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions? Equity includes stock, stock options, and other ownership interests but excludes diversified mutual fund shares.

No

Yes, as described below:

Add rows as needed for each equity interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Patents and Royalties

2. Do you currently or in the past 24 months have you owned patents for or received royalties from any intellectual property or product used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Add rows as needed for each patent or royalty interest.

<i>Company</i>	<i>Description</i>	<i>Date Divested</i>	<i>For ASH Internal Use</i>

Personal Income or Other Remuneration

3. Do you currently or in the past 24 months have you received personal income or other remuneration (e.g., reimbursement or financial support for the costs of travel) from any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company.

Column 2 Describe the activity for which you received income or other remuneration, e.g., employment, consultancy, speakers bureau involvement, service on an advisory committee or board, expert testimony.

Column 3 Indicate when the activity ended, if applicable. (If the activity has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each activity.

To report activities that generate revenues for your institution, see Part B, Question 4.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Industry-Funded Research

4. Do you currently or in the past 24 months have you been involved in research funded or supported (e.g., in kind support) by any for-profit company that develops, produces, markets, or distributes drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions?

No

Yes, as described below:

Column 1 Name the company funding or supporting the research.

Column 2 Briefly describe the research project. Indicate if funding or support goes to you directly or to your institution.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate “current” or “ongoing.”)

Add rows as needed for each research project.

<i>Company</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>	<i>For ASH Internal Use</i>
Myriad Laboratories	Research related to cost-effectiveness of BRCA testing and use of genetic counselors	PI/Co-I	Dec 2016	Not an affected company
AstraZeneca	Outcomes study of BRCA tested breast cancer patients	PI	Jan 2016	AstraZeneca does not have any products related to VTE.
Bristol-Myers Squibb	Patient preference survey in melanoma	Co-I	Dec 2016	NO COI: BMS markets apixaban, however his research is not VTE related. 5/1 Dr. Stenejhem confirmed he reports to a PI and therefore does not have a leadership role.

My Partner’s or Spouse’s Interests

5. Currently or in the past 24 months has *your partner or spouse* had any of the interests described in questions 1-4?

No

Yes, as described below:

Add rows as needed for each interest.

<i>Company</i>	<i>Description</i>	<i>End Date</i>	<i>For ASH Internal Use</i>

Part B. Interests That Are Not Mainly Financial

You have been invited by ASH to participate in the development of clinical practice guidelines on the following topic(s):

Prevention and Treatment of VTE in Patients with Cancer

The questions that follow are designed to elicit information about personal beliefs, intellectual positions or opinions, institutional relationships, and other interests that are not mainly financial and that may be relevant to guidelines on the above topic(s).

Personal Beliefs

1. Do you have strongly held beliefs related to the topic of these guidelines?

No

Yes

If yes, please explain:

Previously Published Opinions

2. Have you ever authored, coauthored, or publicly provided an opinion related to the topic of these guidelines, e.g., a clinical practice guideline, textbook, review article, meeting poster or presentation, grand rounds talk, letter to the editor?

No

Yes

If yes, what were those views and where were they made?

Research

3. Currently or in the past 24 months, have you been involved in a leadership role in any research project not already reported under Part A, Question 4, relevant to the topic of these guidelines, e.g., a research project funded by a nonprofit or governmental organization?

No

Yes, as described below:

Column 1 Name the entity funding the research.

Column 2 Describe the research project.

Column 3 Describe your role: (a) national or overall principal investigator, (b) member of a steering committee of a study that does not have a principal investigator, (c) site or local investigator. If other than these options, please describe.

Column 4 Indicate when your involvement ended, if applicable. (If your involvement has not yet ended, indicate "current" or "ongoing.")

Add rows as needed for each research project.

<i>Funder</i>	<i>Description of Research</i>	<i>My Role</i>	<i>End Date</i>

Institutional Relationships

4. Do you generate revenues or nonfinancial benefits for your institution by teaching, speaking, consulting, testifying, writing, or otherwise sharing your knowledge or opinions about this guideline topic?

Don't know

No

Yes

If yes, please explain:

5. Could your institution benefit or be harmed by recommendations of guidelines on this topic?

Don't know

No

Yes

If yes, please explain:

Career Advancement

6. How would you characterize the support you would receive from your primary mentor, institution, or other entities if your work on this panel or authorship of these guidelines generated a strong reaction from peers outside your institution?

I would be well supported by my Department Chair, Vice-chair, and by my institution.

Advocacy and Policy Positions

7. Do you work for or are you a member of an organization with a stated position related to the topic of these guidelines, e.g., position statement, editorial, blog, amicus brief, or legislature or legal testimony?

No

Yes

If yes, are you involved in formulating or voting for positions?

No

Yes

If yes, could recommendations of these guidelines conflict with policies you have promoted or are obligated to follow?

Don't know or not applicable

No

Yes

If yes, please explain:

Professional Specialty

8. What is your primary clinical specialty or subspecialty?

Clinical pharmacy practice in GI oncology and I am an outcomes researcher.

9. Do you prescribe or otherwise recommend diagnostic tests or treatments that may be addressed by these guidelines?

No

Yes

If yes, please explain:

VTE is commonly encountered in GI oncology and therefore as a clinical pharmacist I help devise treatment plans to prevent or treat VTE in cancer patients.

Expected Interests

10. Do you expect new financial or nonfinancial interests relevant to the topic of these guidelines not already declared in Part A or Part B of this form?

No

Yes

If yes, please describe:

Part C. Summary (ASH Internal Use)

ASH will review your disclosures and summarize here interests that are judged to be current, material, and with an affected company. You will then be invited to review our determinations and to agree to make all parts of this form (A, B and C) publically available.

Name of guideline panel(s)	Guideline Panel on Prevention and Treatment of VTE in Patients with Cancer
----------------------------	--

<i>Approved to participate?</i>	<i>Status</i>	<i>Recusal may be required?</i>	<i>Reviewer Name and Date</i>	<i>Notes</i>
Yes	Unconflicted majority	Yes	4/27/2015; 5/5/2015	
Yes			6/8/2020 Alexander	On 6/3/2020, Dr. Stenehjem confirmed all information in this form.

If status is conflicted minority, summarize all current material interests in affected companies:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Notes</i>

Notes:

Part D. New Declarations

The following interests were disclosed after appointment:

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
Salarius Pharmaceuticals	Direct payment for consulting on Phase I clinical trial	6/3/2020	Not a COI. Salarius Pharmaceuticals does not market any drugs used in the treatment of VTE.
Iterion Therapeutics	Direct payment for consulting on phase I clinical trial	6/3/2020	Not a COI. Iterion Therapeutics does not market any drugs used in the treatment of VTE.
Dracen Pharmaceuticals	Direct payment for consulting on phase I clinical trial	6/3/2020	Not a COI. Dracen Pharmaceuticals does not market any drugs used in the treatment of VTE.
Novartis	Research funding for studies of AML and MDS. Dr. Stenehejm is the coinvestigator.	6/3/2020	Not a COI. Novartis does not market any drugs used in the treatment of VTE. Furthermore, the subject of the research is not related to the guideline topic, Dr. Stenehejm does not have a leadership role, and all funding goes to his institution.
University of Utah	Institutional funding for study of thromboprophylaxis in cancer patients. Dr. Stenehejm is coinvestigator.	6/3/2020	Not a COI. The University of Utah is an academic institution and does not market any drugs used in the treatment of VTE. This is an update to Part B, Question 3.
AstraZeneca	Observational outcomes study of lung cancer patients. Dr. Stenehejm is PI.	6/3/2020	Not a COI. AstraZeneca does not market any drugs used in the treatment of VTE. Furthermore, the subject of the research is not related to the guideline topic and all

<i>Company</i>	<i>Description</i>	<i>Disclosure Date</i>	<i>ASH Internal Notes</i>
			funding goes to his institution.
Bristol Myers Squibb	Observational outcomes study of lung cancer patients. Dr. Stenehejm is the PI.	6/3/2020	Not a COI. BMS markets apixaban and Dr. Stenehejm has a leadership role, however the subject of the research is unrelated to the guideline topic and all funding goes to his institution.